Text Size
142 studies found for:    regeneron

Modify this search | How to Use Search Results

Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Cancel
Rank Status Study
1 Completed
Has Results 		Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)
Condition: Macular Edema Secondary to Central Retinal Vein Occlusion
Interventions: Biological: VEGF Trap-Eye 2.0mg;   Drug: Sham
2 Completed A Study to Evaluate the Safety and Efficacy of Subcutaneously Administered REGN475(SAR164877) in Patients With Sciatic Pain
Condition: Sciatica
Interventions: Drug: REGN475;   Drug: Placebo Injection
3 Recruiting Study of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (Odyssey Alternative)
Condition: Hypercholesterolemia
Interventions: Drug: alirocumab (REGN727/ SAR236553);   Drug: Active Comparator 1 (ezetimibe);   Drug: Active Comparator 2 (atorvastatin);   Other: Placebo 1 (placebo for ezetimibe atorvastatin);   Other: Placebo 2 [alirocumab (REGN727/ SAR236553)]
4 Recruiting Study of the Efficacy and Safety of REGN727 (SAR236553) in Combination With Other Lipid-modifying Treatments (LMT)
Condition: Hypercholesterolemia
Interventions: Drug: REGN727 (SAR236553);   Drug: Atorvastatin;   Drug: Ezetimibe;   Drug: Rosuvastatin;   Other: Placebo
5 Recruiting Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection)
Condition: Age - Related Macular Degeneration (AMD)
Intervention: Drug: Intravitreal Aflibercept Injection (IAI)
6 Recruiting Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT)
Condition: Hypercholesterolemia
Interventions: Drug: alirocumab (REGN727/ SAR236553);   Other: placebo;   Drug: Rosuvastatin;   Drug: Ezetimibe
7 Recruiting A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies
Condition: Advanced Solid Malignancies
Intervention: Drug: REGN421(SAR153192)
8 Recruiting Nesvacumab (REGN910/ SAR307746) and Aflibercept ("Ziv-aflibercept" in the U.S.) in Patients With Advanced Solid Malignancies
Condition: Solid Tumors
Interventions: Drug: nesvacumab (REGN910/ SAR307746);   Drug: aflibercept (ziv-aflibercept)
9 Recruiting Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer
Condition: Cancer
Interventions: Drug: REGN1400;   Drug: Erlotinib;   Drug: Cetuximab
10 Recruiting Study to Assess the Safety and Tolerability of Single Doses of REGN1500
Condition: Healthy Volunteers
Interventions: Drug: REGN1500;   Drug: Placebo
11 Recruiting Study of Dupilumab (REGN668/ SAR231893) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Condition: Atopic Dermatitis
Interventions: Drug: Dupilumab (REGN668/ SAR231893);   Drug: Placebo
12 Recruiting The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy
Condition: Central Serous Chorioretinopathy
Intervention: Drug: Intravitreal Aflibercept Injection
13 Completed Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Condition: Cancer
Intervention: Biological: ziv-aflibercept
14 Completed Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Condition: Cancer
Intervention: Biological: ziv-aflibercept
15 Completed VEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin's Lymphoma
Conditions: Lymphoma;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Biological: ziv-aflibercept
16 Completed VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma
Conditions: Lymphoma;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Biological: ziv-aflibercept
17 Not yet recruiting Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea
Condition: Corneal Neovascularization
Interventions: Drug: Subconjunctival aflibercept;   Other: Placebo: Standard of care only
18 Completed Internleukin-1 Trap to Treat Autoinflammatory Disease
Conditions: Inflammation;   Familial Mediterranean Fever;   Still's Disease, Adult-Onset
Intervention: Drug: IL-1 Trap
19 Completed Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of REGN668 Administered Subcutaneously to Healthy Volunteers
Condition: Healthy
Interventions: Drug: REGN668: Injection Rate 1;   Drug: REGN668: Injection Rate 2
20 Active, not recruiting Study of Alirocumab (REGN727/ SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy)
Condition: Heterozygous Familial Hypercholesterolemia
Interventions: Drug: LMT (atorvastatin, simvastatin, or rosuvastatin);   Drug: alirocumab (REGN727/ SAR236553);   Other: Placebo
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years